drugset / Trial / NCT04218968

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

NCT04218968

Phase 2 Active not recruiting 15 enrolled Cedars-Sinai Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the long-term effects of treatment with the adrenergic blocker carvedilol on serial DaTscan, a dopamine transporter (DAT) single photon emission computerized tomography (SPECT) imaging technique in a population of subjects with defined pre-motor Parkinson's disease risks (i.e., REM sleep Behavior Disorder (RBD) and at least one among hyposmia, constipation, depression and color vision abnormality) and abnormal 123I-Metaiodobenzylguanidine (MIBG) scintigraphy.

Timeline

Start
2019-12-30
Primary completion
2026-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 12.5 mg Oral
Subject Carvedilol Other / unclassified 25 mg Oral